WAVE Life Sciences (WVE) Stock Price, News & Analysis

Company Overview

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications. Several assets are advancing through preclinical research and clinical trials, and WAVE collaborates with biopharmaceutical partners to co-develop selected candidates and expand the reach of its technology into new disease areas.

WAVE’s research and development activities are anchored in its laboratories in Cambridge, Massachusetts, where multidisciplinary teams of chemists, biologists and clinical scientists work to translate novel oligonucleotide designs into development candidates. The company also maintains strategic collaborations and research partnerships in North America and Asia, aiming to accelerate global access to its therapies and support regulatory filings in multiple jurisdictions.

Founded in 2015, WAVE Life Sciences has built a leadership team with deep expertise in RNA biology, medicinal chemistry and drug development. The company continues to refine its stereopure oligonucleotide platform to address delivery challenges, improve pharmacokinetics and expand its pipeline across a broad range of genetic and rare diseases.

Key Stats

• Today's Range: $5.24 to $5.46
• 50-Day Range: $5.05 to $6.38
• 52-Week Range: $5.01 to $21.73
• Volume: 3.51 million shs
• Average Volume: 3.88 million shs
• Market Capitalization: $1.04 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.53
• Consensus Rating: Moderate Buy

WAVE Life Sciences Stock Analysis - MarketRank™

WAVE Life Sciences scored higher than 66% of companies evaluated by MarketBeat, and ranked 284th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

WAVE Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 1 strong buy rating, 14 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

WAVE Life Sciences has a consensus price target of $22.53, representing about 325.7% upside from its current price of $5.29.

Amount of Analyst Coverage

WAVE Life Sciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for WAVE Life Sciences are expected to decrease in the coming year, from ($1.12) to ($1.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of WAVE Life Sciences is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of WAVE Life Sciences is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

WAVE Life Sciences has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.00% of the float of WAVE Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

WAVE Life Sciences has a short interest ratio ("days to cover") of 7.45.

Change versus previous month

Short interest in WAVE Life Sciences has recently decreased by 2.65%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

WAVE Life Sciences does not currently pay a dividend.

Dividend Growth

WAVE Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.51

News Sentiment

WAVE Life Sciences has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for WAVE Life Sciences this week, compared to 6 articles on an average week.

Search Interest

35 people have searched for WVE on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.

MarketBeat Follows

6 people have added WAVE Life Sciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, WAVE Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.30% of the stock of WAVE Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

89.73% of the stock of WAVE Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:WVE
• CIK: 1631574
• Web: www.wavelifesciences.com
• Phone: (656) 236-3388
• Fax: 617-949-2901
• Employees: 240
• Year Founded: 2012

Price Target and Rating

• Average Price Target for WAVE Life Sciences: $22.53
• High Price Target: $43.00
• Low Price Target: $12.00
• Potential Upside/Downside: +325.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.94
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$204.38 million
• Net Margins: -309.73%
• Pretax Margin: -309.73%
• Return on Equity: -50.36%
• Return on Assets: -40.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.99
• Quick Ratio: 9.99

Sales & Book Value

• Annual Sales: $42.73 million
• Price / Sales: 24.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.30 per share
• Price / Book: 2.30

Miscellaneous

• Outstanding Shares: 197,050,000
• Free Float: 149,165,000
• Market Cap: $1.04 billion
• Optionable: Optionable
• Beta: -1.26